Evaluation of the effect of Memantine in patients with brain tumors

The effect of Memantine on cognitive impairment in patients with brain tumor under radiotherapy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211029052903N1

Enrollment

Registered

2023-01-17

Start date

2022-01-21

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Impairment. Mild cognitive impairment, so stated

Interventions

Intervention 1: Intervention group: Daily intake of two 5 mg memantine tablets 12 hours after a meal for 6 weeks. Intervention 2: Control group: Receiver of a placebo pill similar to Memantine at the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with a brain tumor Candidate for radiotherapy Satisfaction to participate in the study

Exclusion criteria

Exclusion criteria: Drug allergy to memantine History of neurological disorders

Design outcomes

Primary

Measure	Time frame
Cognitive Impariment. Timepoint: Before and 6 weeks after the start of the intervention. Method of measurement: Mini-Mental State Exam(MMSE).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSimin Hemati

Esfahan University of Medical Sciences

s_hemati@med.mui.ac.ir+98 31 3669 2174

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026